162 related articles for article (PubMed ID: 29185262)
1. Mutational analysis of KRAS and its clinical implications in cervical cancer patients.
Jiang W; Xiang L; Pei X; He T; Shen X; Wu X; Yang H
J Gynecol Oncol; 2018 Jan; 29(1):e4. PubMed ID: 29185262
[TBL] [Abstract][Full Text] [Related]
2. Precise Classification of Cervical Carcinomas Combined with Somatic Mutation Profiling Contributes to Predicting Disease Outcome.
Spaans VM; Trietsch MD; Peters AA; Osse M; Ter Haar N; Fleuren GJ; Jordanova ES
PLoS One; 2015; 10(7):e0133670. PubMed ID: 26197069
[TBL] [Abstract][Full Text] [Related]
3. Impact of HPV 16/18 infection on clinical outcomes in locally advanced cervical cancers treated with radical radio (chemo) therapy - A prospective observational study.
Mahantshetty U; Teni T; Naga P; Hotwani C; Umesh S; Kannan S; Hande V; Pawar S; Engineer R; Chopra S; Deodhar K; Maheshwari A; Gurram L; Gupta S; Shrivastava SK
Gynecol Oncol; 2018 Feb; 148(2):299-304. PubMed ID: 29203175
[TBL] [Abstract][Full Text] [Related]
4. Analysis and clinical implications of K-ras gene mutations and infection with human papillomavirus types 16 and 18 in primary adenocarcinoma of the uterine cervix.
Tenti P; Romagnoli S; Silini E; Pellegata NS; Zappatore R; Spinillo A; Zara C; Ranzani GN; Carnevali L
Int J Cancer; 1995 Feb; 64(1):9-13. PubMed ID: 7665253
[TBL] [Abstract][Full Text] [Related]
5. HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis.
Rodríguez-Carunchio L; Soveral I; Steenbergen RD; Torné A; Martinez S; Fusté P; Pahisa J; Marimon L; Ordi J; del Pino M
BJOG; 2015 Jan; 122(1):119-27. PubMed ID: 25229645
[TBL] [Abstract][Full Text] [Related]
6. Low mutation percentage of KRAS and BRAF genes in Brazilian anal tumors.
Bidinotto LT; Véo CA; Loaiza EA; De França AP; Lorenzi AT; Rosa LA; De Oliveira CM; Levi JE; Scapulatempo-Neto C; Longatto-Filho A; Reis RM
Mol Med Rep; 2016 Oct; 14(4):3791-7. PubMed ID: 27573925
[TBL] [Abstract][Full Text] [Related]
7. Correlation between human papillomavirus positivity and p53 gene overexpression in adenocarcinoma of the uterine cervix.
Uchiyama M; Iwasaka T; Matsuo N; Hachisuga T; Mori M; Sugimori H
Gynecol Oncol; 1997 Apr; 65(1):23-9. PubMed ID: 9103386
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.
Wright AA; Howitt BE; Myers AP; Dahlberg SE; Palescandolo E; Van Hummelen P; MacConaill LE; Shoni M; Wagle N; Jones RT; Quick CM; Laury A; Katz IT; Hahn WC; Matulonis UA; Hirsch MS
Cancer; 2013 Nov; 119(21):3776-83. PubMed ID: 24037752
[TBL] [Abstract][Full Text] [Related]
9. Prevalence, distribution, and viral burden of all 15 high-risk human papillomavirus types in adenosquamous carcinoma of the uterine cervix: a multiplex real-time polymerase chain reaction-based study.
Quddus MR; Manna P; Sung CJ; Kerley S; Steinhoff MM; Lawrence WD
Hum Pathol; 2014 Feb; 45(2):303-9. PubMed ID: 24355194
[TBL] [Abstract][Full Text] [Related]
10. Analysis and clinical implications of p53 gene mutations and human papillomavirus type 16 and 18 infection in primary adenocarcinoma of the uterine cervix.
Tenti P; Pavanello S; Padovan L; Spinillo A; Vesentini N; Zappatore R; Migliora P; Zara C; Ranzani GN; Carnevali L
Am J Pathol; 1998 Apr; 152(4):1057-63. PubMed ID: 9546366
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive mapping of the human papillomavirus (HPV) DNA integration sites in cervical carcinomas by HPV capture technology.
Liu Y; Lu Z; Xu R; Ke Y
Oncotarget; 2016 Feb; 7(5):5852-64. PubMed ID: 26735580
[TBL] [Abstract][Full Text] [Related]
12. ERBB2 mutation: A promising target in non-squamous cervical cancer.
Xiang L; Jiang W; Ye S; He T; Pei X; Li J; Chan DW; Ngan HYS; Li F; Tao P; Shen X; Zhou X; Wu X; Yang G; Yang H
Gynecol Oncol; 2018 Feb; 148(2):311-316. PubMed ID: 29279289
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus DNA in cervical carcinoma--correlation with clinical data and influence on prognosis.
Ikenberg H; Sauerbrei W; Schottmüller U; Spitz C; Pfleiderer A
Int J Cancer; 1994 Nov; 59(3):322-6. PubMed ID: 7927936
[TBL] [Abstract][Full Text] [Related]
14. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus localization in cervical adenocarcinoma and adenosquamous carcinoma using in situ polymerase chain reaction: review of the literature of human papillomavirus detection in these carcinomas.
Ogura K; Ishi K; Matsumoto T; Kina K; Nojima M; Suda K
Pathol Int; 2006 Jun; 56(6):301-8. PubMed ID: 16704493
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 2 different PCR-based technologies for the detection of human papilloma virus from paraffin-embedded tissue: genómica clinical arrays versus SPF(10)-LiPA(25).
Pérez C; Klaustermeier JE; Alemany L; Tous S; de Sanjosé S; Velasco J
Diagn Mol Pathol; 2012 Mar; 21(1):45-52. PubMed ID: 22306675
[TBL] [Abstract][Full Text] [Related]
17. Homozygous arginine at codon 72 of p53 has no prognostic significance in cervical cancer.
Ngan HY; Liu VW; Liu SS; Cheng DK; Ng TY; Wong LC
Tumour Biol; 2000; 21(3):135-8. PubMed ID: 10754463
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus DNA in adenocarcinoma and adenosquamous carcinoma of the uterine cervix detected by polymerase chain reaction (PCR).
Yamakawa Y; Forslund O; Teshima H; Hasumi K; Kitagawa T; Hansson BG
Gynecol Oncol; 1994 May; 53(2):190-5. PubMed ID: 8188078
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study.
de Sanjose S; Quint WG; Alemany L; Geraets DT; Klaustermeier JE; Lloveras B; Tous S; Felix A; Bravo LE; Shin HR; Vallejos CS; de Ruiz PA; Lima MA; Guimera N; Clavero O; Alejo M; Llombart-Bosch A; Cheng-Yang C; Tatti SA; Kasamatsu E; Iljazovic E; Odida M; Prado R; Seoud M; Grce M; Usubutun A; Jain A; Suarez GA; Lombardi LE; Banjo A; Menéndez C; Domingo EJ; Velasco J; Nessa A; Chichareon SC; Qiao YL; Lerma E; Garland SM; Sasagawa T; Ferrera A; Hammouda D; Mariani L; Pelayo A; Steiner I; Oliva E; Meijer CJ; Al-Jassar WF; Cruz E; Wright TC; Puras A; Llave CL; Tzardi M; Agorastos T; Garcia-Barriola V; Clavel C; Ordi J; Andújar M; Castellsagué X; Sánchez GI; Nowakowski AM; Bornstein J; Muñoz N; Bosch FX;
Lancet Oncol; 2010 Nov; 11(11):1048-56. PubMed ID: 20952254
[TBL] [Abstract][Full Text] [Related]
20. Low incidence of KRAS, BRAF, and PIK3CA mutations in adenocarcinomas of the ampulla of Vater and their prognostic value.
Kwon MJ; Kim JW; Jung JP; Cho JW; Nam ES; Cho SJ; Kim JS; Park HR; Min SK; Seo J; Min KW; Kim DH; Jeon JY
Hum Pathol; 2016 Apr; 50():90-100. PubMed ID: 26997442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
